Upstream Bio announced pivotal Phase 3 development plans for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) following FDA discussions. The company will conduct separate placebo-controlled trials enrolling approximately 1,500 patients total, evaluating a single high-dose subcutaneous regimen of 400mg administered every 12 weeks. Primary endpoints include annualized asthma exacerbation rates for asthma and changes in nasal polyp and congestion scores for CRSwNP over 48 weeks. Phase 3 trials are scheduled to initiate in the first quarter of 2027, with potential Biologics License Application submission and launch as early as 2030 if results are supportive. Upstream Bio is a clinical-stage biotechnology company developing treatments for severe inflammatory respiratory diseases.

Upstream Bio reported second quarter 2026 financial results and clinical updates. The company had cash, cash equivalents, and short-term investments of $261.3 million as of June 30, 2026, sufficient to fund operations through 2027. R&D expenses were $36.1 million and G&A expenses were $7.1 million, resulting in a net loss of $39.7 million compared to a $40.0 million loss in the prior year period. Clinically, Upstream Bio remains on track to initiate Phase 3 trials for severe asthma and CRSwNP in Q1 2027 following End-of-Phase 2 FDA interactions. Enrollment was completed in the Phase 2 VENTURE trial in COPD with 481 participants, with data expected in H2 2027. Upstream Bio is a clinical-stage biotechnology company developing treatments for severe inflammatory respiratory diseases.